Evolution of consumption of high-cost drugs in Colombia;Evolución del consumo de medicamentos de alto costo en Colombia

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 31, Issue 4, 2012, Pages 283-289

  Alba, Jorge Enrique Machado ^a   Escobar, Juan Carlos Moncada ^a  

^a AUDIFARMA S A   (Colombia)

Author keywords

Colombia; Cost control; Drug substitution; Drug utilization; Economics; Financing; Health; Health policy; Pharmaceutical

Indexed keywords

PRESCRIPTION DRUG;

COST-BENEFIT ANALYSIS; DRUG; DRUG PRESCRIBING; HEALTH POLICY; HEALTH SERVICES; INFECTIOUS DISEASE; NERVOUS SYSTEM; SOCIAL SECURITY; WILLINGNESS TO PAY; WORLD HEALTH ORGANIZATION;

ARTICLE; COLOMBIA; DRUG COST; DRUG UTILIZATION; ECONOMICS; HUMAN; STATISTICS;

COLOMBIA; DRUG COSTS; DRUG UTILIZATION; HUMANS; PRESCRIPTION DRUGS;

COLOMBIA;

EID: 84864216252     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892012000400003     Document Type: Article

References (27)

1. Laing R, Waning B, Gray A, Ford N, 't Hoen E. 25 years of the WHO essential medicines lists: progress and challenges. Lancet. 2003;361:1723-9. (Pubitemid 36577449)
2. Seuba X. A human rights approach to the WHO Model List of Essential Medicines. Bull World Health Organ. 2006;84(5):405-7.
3. Ashcroft RE. Access to essential medicines: a Hobbesian social contract approach. Dev World Bioeth. 2005;5(2):121-41. (Pubitemid 40675090)
4. Drummond M, Mason A. European perspective on the costs and cost-effectiveness of cancer therapies. Journal of Clinical Oncology. 2007;25(2):191-5. (Pubitemid 350003033)
5. Lu CY, Williams KM, Day RO. Access to tumour necrosis factor inhibitors for rheumatoid arthritis treatment under the Australian Pharmaceutical Benefits Scheme: are we on target? Intern Med J. 2006;36(1):19-27. (Pubitemid 43362543)
6. Bartlett JA, Muro EP. Generic and Branded Drugs for the Treatment of People Living with HIV/AIDS. J Int Assoc Physicians AIDS Care (Chic). 2007;6(1):15-23.
7. Campos-Olazabal P. Risks and benefits of the new antiepileptic drugs. Rev Neurol. 2006; 42(3):57-60.
8. Rojo P. El acceso a los medicamentos esenciales en los países pobres. Gac Sanit. 2001; 15(6):540-5.
9. Faunce TA. The UNESCO Bioethics Declaration 'social responsibility' principle and cost-effectiveness price evaluations for essential medicines. Monash Bioeth Rev. 2005;24(3): 10-9.
10. Garenne M, Candau D, Guimier JM, Badiane M, Diop AC, Teuliéres LC. Access to medicines in Senegal: results of a sample survey. Trop Doct. 2006;36(1):5-8. (Pubitemid 43242222)
11. Hogerzeil HV, Samson M, Vidal Casanovas J, Rahmani-Ocora L. Is access to essential medicines as part of the fulfillment of the right to health enforceable through the courts? Lancet. 2006;368:305-11. (Pubitemid 44067247)
12. Ministerio de Salud de Colombia. Consejo Nacional de Seguridad Social en Salud. Acuerdo 228 de 2002. Disponible en: http://www.col.ops-oms.org/ medicamentos/Documentos/ac228-02.htm Acceso el 21 de noviembre de 2011.
13. Ministerio de la Protección Social de Colombia. Consejo Nacional de Seguridad Social en Salud. Acuerdo 282 de 2004. Disponible en: http://www.cntv.org.co/cntv-bop/basedoc/acuerdo/cnsss/acuerdo-cnsss-0282-2004. html Acceso el 9 de enero de 2012.
14. Ministerio de la Protección Social de Colombia. Consejo Nacional de Seguridad Social en Salud. Acuerdo 0336 de 2006. Disponible en: http://www.pos.gov.co/Documents/Archivos/Normatividad-Regimen-Contributivo/ acuerdo-336-2006.pdf Acceso el 21 de noviembre de 2011.
15. Ministerio de la Protección Social de Colombia. Estadísticas: Base de datos única de afiliados, consolidado 2010. Disponible en: http://www.minproteccionsocial.gov.co/estadisticas/default.aspx Acceso el 21 de noviembre de 2011.
16. Niezen MG, Stolk EA, Steenhoek A, Uyl-De Groot CA. Inequalities in oncology care: Economic consequences of high cost drugs. Eur J Cancer. 2006;42(17):2887-92. (Pubitemid 44667478)
17. Cohen J, Wilson A. New challenges to medicare beneficiary access to mAbs. MAbs. 2009; 1(1):56-66.
18. Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008;23(1):CD007017.
19. Barros PP, Nunes LC. The impact of pharmaceutical policy measures: anendogenous structural-break approach. Soc Sci Med. 2010; 71(3):440-50.
20. Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2007;18(3):CD006731.
21. Jufang S, Huiyun S. Some views about the high cost of medical care in China. Southeast Asian J Trop Med Public Health. 2010;41(1):240-2.
22. Sax P, Shmueli A. Impact of pharmaceutical regulation and policies on health system performance goals in Israel. Adv Health Econ Health Serv Res. 2010;22:77-101.
23. Barros PP. Pharmaceutical policies in European countries. Adv Health Econ Health Serv Res. 2010;22:3-27.
24. Presidencia de la República de Colombia. Decreto 4975 de 2009. Disponible en: http://www.elabedul.net/Documentos/Leyes/2009/Decreto-4975.pdf Acceso el 21 de noviembre de 2011.
25. Allan GM, Lexchin J, Wiebe N. Physician awareness of drug cost: a systematic review. PLoS Med. 2007;4(9):1486-96. (Pubitemid 47503041)
26. Babar ZU, Ibrahim MI, Singh H, Bukahri NI, Creese A. Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia. PLoS Med. 2007;4:466-75. (Pubitemid 46495314)
27. Velásquez G. El acceso global a los medicamentos en el contexto internacional actual. Biomédica. 2011;31(2):161-3.